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Abstract
AIM: To better understand the pathogenic role of He-
licobacter pylori  (H. pylori ) in pre-eclampsia (PE), and 
whether it is associated or not with fetal growth retar-
dation (FGR).
METHODS: Maternal blood samples were collected 
from 62 consecutive pregnant women with a diagnosis 
of PE and/or FGR, and from 49 women with uneventful 
pregnancies (controls). Serum samples were evaluated 
by immunoblot assay for presence of specific antibodies 
against H. pylori  antigens [virulence: cytotoxin-associ-
ated antigen A (CagA); ureases; heat shock protein B; 
flagellin A; persistence: vacuolating cytotoxin A (VacA)]. 
Maternal complete blood count and liver enzymes levels 
were assessed at delivery by an automated analyzer.
RESULTS: A significantly higher percentage of H. pylori  
seropositive women were found among PE cases (85.7%) 
compared to controls (42.9%, P  < 0.001). There were 
no differences between pregnancies complicated by FGR 
without maternal hypertension (46.2%) and controls. 
Importantly, persistent and virulent infections (VacA/
CagA seropositive patients, intermediate leukocyte blood 
count and aspartate aminotransferase levels) were ex-
clusively associated with pre-eclampsia complicated by 
FGR, while virulent but acute infections (CagA positive/
VacA negative patients, highest leukocyte blood count 
and aspartate aminotransferase levels) specifically cor-
related with PE without FGR.
CONCLUSION: Our data strongly indicate that persis-
tent and virulent H. pylori  infections cause or contrib-
ute to PE complicated by FGR, but not to PE without 
feto-placental compromise.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Pre-eclampsia (PE) is a severe hypertensive pregnancy-re-
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lated disorder that affects 5%-8% of  women worldwide, 
thus representing the main cause of  feto-maternal mor-
tality and morbidity[1,2]. PE is often associated with fetal 
growth retardation (FGR), defined as failure of  the fetus 
to achieve its genetically determined growth potential[3,4]. 
FGR is commonly considered a severe complication of  
PE, but whether or not PE and FGR are manifestations 
of  the same disorder, or two distinct pathologies, still re-
mains unclear.
PE is characterized by excessive maternal inflamma-
tory response, with high circulating levels of  pro-inflam-
matory cytokines and endothelial injury[1,2]. Despite being 
an object of  intense investigation, the etiopathogenetic 
mechanisms of  PE are still poorly understood. Several 
lines of  evidence suggest that subclinical infections could 
play a role in the onset of  PE[5,6].
We previously reported a strong association between 
Helicobacter pylori (H. pylori) infection and PE[7]. H. pylori is 
a Gram-negative bacterium responsible for the large ma-
jority of  peptic ulcers, gastric cancer, and gastric mucosa-
associated lymphoid tissue lymphoma[8]. It has been dem-
onstrated that this pathogen enhances platelets activation 
and thrombus formation[9,10], thus inducing endothelial 
inflammation and injury. Therefore, H. pylori could direct-
ly cause or intensify the generalized inflammation and en-
dothelial dysfunction typical of  PE[7]. Furthermore, it was 
recently observed that H. pylori seropositive PE subjects 
are characterized by a more severe inflammatory status[11] 
and lipid peroxidation[12].
The role of  cytotoxin-associated antigen A (CagA) 
in inducing a severe immunogenic response in patients 
infected by H. pylori is now well established[13]. Neverthe-
less, other virulence factors could be involved in the se-
vere inflammatory response mediated by this bacterium. 
The vacuolating cytotoxin A (VacA) is a protein pro-
duced by H. pylori with several effects on vulnerable cells, 
such as vacuolation with alteration of  the endo-lysosomal 
function and mitochondrial damage accompanied by cy-
tochrome C release and apoptosis[14].
Ureases allow colonization of  the gastric mucosa by 
catalyzing the hydrolysis of  urea and help to recruit neu-
trophils and monocytes in the mucosa, thus inducing pro-
inflammatory cytokines production[15].
Heat shock protein B (HspB) has been shown to in-
crease the risk of  gastric carcinoma, by directly inducing hy-
per-proliferation of  gastric cells[16]. Moreover, it strongly ac-
tivates the immune system and stimulates a massive immune 
response in patients with gastritis and gastric cancer[17-19].
To better understand the pathogenic role of  H. pylori 
in pre-eclampsia, we investigated maternal serum positiv-
ity for antibodies against CagA, VacA, HspB, ureases A, 
C, E and H (UreA, UreC, UreE, UreH), and for flagellin 
A (FlagA). FlagA is the major H. pylori flagellin isoform, 
mainly expressed during late exponential growth phase 
and represents a good H. pylori virulence index[20].
To correlate H. pylori virulence with PE severity, and 
to detect differences in H. pylori profiles between PE and 
FGR pregnancies, we determined seropositivity for the 
above mentioned antigens in three populations: PE with-
out FGR, PE complicated by FGR, and FGR without PE.
Finally, we verified the reported association between 
H. pylori infection and elevated leukocyte blood count and 
serum amino-transferases levels[21].
MATERIALS AND METHODS
Population and samples
The study was approved by our Hospital Ethics Commit-
tee “Comitato Etico Interaziendale AA.OO O.I.R.M./
S.Anna di Torino and Ordine Mauriziano di Torino” and 
written informed consent was obtained from each par-
ticipating woman.
Maternal blood samples (5 mL) were collected before 
delivery from 62 consecutive pregnant women with di-
agnosis of  PE and/or FGR, and from 49 women with 
normotensive pregnancies with normal fetal growth and 
normal uterine and umbilical Doppler flow velocimetry 
(FVW).
PE was diagnosed when hypertension (systolic blood 
pressure ≥ 140 mmHg or diastolic blood pressure ≥ 
90 mmHg) and proteinuria (≥ 300 mg/24 h) appeared 
after 20 wk of  gestational age in previously normotensive 
women, according to the American College of  Obstetri-
cians and Gynecologists criteria[22]. PE was considered 
severe when one or more of  the following criteria were 
present: systolic pressure ≥ 160 mmHg or diastolic pres-
sure ≥ 110 mmHg on two occasions at least 6 h apart, 
or significant proteinuria (≥ 3 + on urine dipstick or > 5 g 
in a 24-h urine)[22]. Patients with PE were further classi-
fied as either having early-onset (≥ 34 wk), or late-onset 
(> 34 wk) disease according to the gestational age of  PE 
diagnosis.
The hemolysis-elevated liver enzymes-low platelets 
(HELLP) syndrome was defined by the following crite-
ria: hemolysis (characteristic peripheral blood smear and 
serum lactate dehydrogenase ≥ 600 U/L), elevated liver 
enzymes (serum aspartate aminotransferase ≥ 70 U/L), 
and low platelet count (< 100  000/μL)[23].
The diagnosis of  FGR was made according to the 
following criteria: ultrasound measurement of  fetal 
abdominal circumference below the 10th centile[24] or 
growth velocity below the 10th percentile[25] and/or birth 
weight below the 10th centile, according to Italian refer-
ence values[26] with abnormal umbilical arteries Doppler 
FVWs[27] and/or abnormal uterine artery Doppler FVWs 
(resistance index of  > 0.58)[28]. Exclusion criteria were: 
multiple pregnancies, congenital malformations, and pre-
natal or postnatal diagnosis of  chromosomal anomalies 
in number and/or structure. 
For all cases and controls, the following data were col-
lected: maternal age at delivery, gestational age at birth, 
week of  PE onset, mode of  delivery, neonatal sex, birth 
weight, placental weight, parity, blood pressure, urinary 
protein, complete blood count and differentials (count 
and percentage of  neutrophils, lymphocytes, monocytes, 
eosinophils, and basophils), liver enzymes levels, risk 
factors for PE (previous pregnancy with PE, autoim-
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mune diseases, diabetes, cardiovascular diseases, or other 
common risk factors for PE), and family history of  pre-
eclampsia and/or cardiovascular diseases.
Venous blood samples were collected into Vacutainer 
tubes (Becton Dickinson, Plymouth, United Kingdom) 
without anticoagulant. Serum was separated by centrifu-
gation immediately after clotting and stored at -30  ℃ 
until assayed.
Serology
Serum samples were evaluated for specific antibodies 
against H. pylori antigens by commercially available Heli-
Blot assay (Nurex; Sassari, Italy). H. pylori seropositivity 
was determined according to manufacturer instructions. 
Briefly, diluted serum samples (1:100) were incubated 
with Heli-Blot strips for 30 min. The strips were then 
incubated consecutively with anti-IgG for 30 min, with 
substrate for range of  minutes, and then dried. Results 
were read according to the standard control protein bands 
provided. The standard H. pylori antigens available in the 
strip included: 120 kDa (CagA), 89 kDa (VacA), 60 kDa 
(Urease C), 54 kDa (HSP), 35 kDa (Flagellin), 30 kDa 
(Urease H), 26 kDa (Urease A), and 19 kDa (Urease E). 
The presence of  one of  the three most specific antigens 
(CagA, VacA, or flagellin) or the presence of  two of  the 
three smallest antigens was considered a positive test for 
the diagnosis of  H. pylori infection.
Statistical analysis
Data analysis was performed using SPSS version 17.0  
(SPSS Inc., Chicago, Illinois, United States). Continuous 
variables were reported as medians and interquartile rang-
es (25th-75th percentiles). Medians among groups were 
analyzed by non-parametric Kruskal-Wallis H test, with 
post-hoc analysis by Mann-Whitney U test. Categorical 
variables are presented as frequencies (percentages) and 
the comparison between different groups was done with 
a χ 2 test by means of  a 2 × 2 contingency table; Fisher’
s exact test was used for small sample sizes. All tests were 
2-tailed and results were considered significant for a P 
value less than 0.05. The odds ratios (OR) and 95% confi-
dence intervals (CI), adjusted for maternal age at delivery, 
pre-pregnancy body mass index, parity, presence of  ma-
ternal and family risk factors, were calculated using logistic 
regression analysis to assess the risk of  PE and/or FGR 
associated with H. pylori infection.
RESULTS
Population
A total of  111 serum samples from pregnant women 
were examined: 49 uneventful pregnancies (Ctrl) and 62 
pathological pregnancies complicated by fetal growth 
retardation (FGR-only, n = 13), pre-eclampsia (PE-only, n 
= 17), or both (PE-FGR, n = 32). Characteristics of  the 
study population are summarized in Tables 1 and 2.
We found that normotensive women with pregnancy 
complicated by FGR were significantly younger (median 
of  25 years with an interquartile range of  24-26 years) 
compared to controls and PE women (both with a median 
age of  30 years). As expected, pregnancies complicated by 
PE and/or FGR were delivered more often by caesarean 
section. Moreover, pathological cases led to lower neo-
natal and placental weight compared to controls, due to 
lower gestational age at delivery and reduced fetal growth.
Pre-eclamptic mothers presented higher blood pres-
sure values and urine protein concentrations. The pres-
ence of  family risk factors was increased in PE cases 
without FGR (Table 2), while maternal risk factors for 
PE did not differ among groups (Table 2). The percent-
age of  nulliparous women was significantly higher in the 
PE group than in controls. In 45 PE mothers, hyperten-
sion and proteinuria appeared early (before 34 wk) and in 
32 of  them these symptoms were severe; moreover five 
PE pregnancies were complicated by HELLP syndrome.
Leukocyte blood count, platelet count, and serum 
amino-transferases values in normal and pathologic 
pregnancies
Pre-eclamptic pregnancies were characterized by signifi-
cantly higher values of  total leukocyte count (P = 0.004) 
and serum amino-transferases [alanine aminotransferase 
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Table 1  Clinical characteristics of study populations (continuous variables)
Variable Controls (n  = 49)
Median (25th-75th)
PE-only (n  = 17)
Median (25th-75th)
PE FGR (n  = 32)
Median (25th-75th)
FGR-only (n  = 13)
Median (25th-75th)
P  value1
Maternal age at delivery (yr)     30 (28-33)4     29 (24-32)     30 (26-34)7     25 (24-26)4,7      4< 0.001; 70.002
Gestational age at delivery (wk)     40 (39-41)2,3,4     30 (28-31)2,5,6     32 (31-34)3,5     34 (32-39)4,6   2,3,4< 0.001; 
               50.045; 60.009
Neonatal weight (g) 3380 (3170-3700)2,3,4 1140 (1045-1570)2 1278 (920-1668)3 1600 (1060-2730)4   2,3,4< 0.001
Placental weight (g)   600 (500-650)2,3,4   300 (240-410)2   280 (215-360)3   345 (300-470)4   2,3,4< 0.001
Systolic blood pressure (mmHg)   120 (110-120)2,3   160 (150-160)2,6   150 (148-160)3,7   120 (120-125)6,7 2,3,6,7< 0.001
Diastolic blood pressure 
(mmHg)
    75 (70-80)2,3   100 (100-100)2,6   100 (95-105)3,7     77 (75-80) 6,7 2,3,6,7< 0.001
Proteinuria (g/24 h)       0 (0-0)2,3  2.21 (1.52-3)2,6  1.34 (0.79-2.38)3,7       0 (0-0)6,7 2,3,6,7< 0.001
1P values were calculated by non-parametric Kruskal-Wallis H test, with post-hoc analysis by Mann-Whitney U test. 2Comparison between controls and PE-
only group; 3Comparison between Controls and PE FGR group; 4Comparison between controls and FGR-only group; 5Comparison between PE-only and 
PE FGR groups; 6Comparison between PE-only and FGR-only groups; 7Comparison between PE-only and FGR-only groups. PE: Pre-eclampsia; FGR: Fetal 
growth retardation.
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(ALT), aspartate aminotransferase (AST) P = 0.006 and 
P = 0.029, respectively], while eosinophil count and 
percentage were significantly lower (P = 0.028 and P = 
0.02, respectively) compared to controls. However, if  
we exclude pathological cases complicated by HELLP 
syndrome, only ALT levels remained significantly higher 
in PE (Table 3). Normotensive pregnancies complicated 
by FGR showed significantly higher leukocyte levels 
compared to controls (P = 0.045, Table 3). Moreover, the 
FGR-only lymphocyte percentage was significantly higher 
relative to PE-only (P = 0.047, Table 3).
H. pylori seropositivity was increased in PE-FGR but not 
in FGR-only pregnancies
H. pylori seropositivity was significantly more frequent 
in PE women with or without FGR (85.7%) (P < 0.001; 
OR 9.22, 95% CI: 2.83-30.04), while it did not differ 
between FGR-only (46.2%) and controls (42.9%) (Table 4, 
Figure 1A). Further subdivision of  PE group showed a 
higher prevalence of  seropositive subjects among PE-
FGR cases (93.8%) (P < 0.001; OR 35.56, 95% CI: 
5.22-242.43) compared to controls; while in the PE-only 
group, the percentage of  H. pylori seropositive women 
was higher, but not statistically significant (70.6%), rela-
tive to controls (Table 4, Figure 1A).
CagA and VacA seropositivity was increased in 
pre-eclamptic but not in FGR-only pregnancies
Similar to H. pylori seropositivity, the presence of  anti-
bodies against CagA antigen was prevalent only in PE 
pregnant women (81.6%) relative to controls (22.4%) (P 
< 0.001; OR 17.66, 95% CI: 5.25-59.49), while there were 
no differences between FGR-only cases (38.5%) and 
controls (Table 4, Figure 1B). CagA seropositivity was 
significantly more frequent in both PE-FGR (90.6%) (P 
< 0.001; OR 54.97, 95% CI: 9.24-326.88) and PE-only 
groups (64.7%) (P = 0.038; OR 5.20, 95% CI: 1.09-24.69), 
relative to controls. VacA seropositivity was significantly 
higher in PE-FGR cases (87.5%) (P < 0.001; OR 19.64, 
95% CI: 3.75-102.98), while there were no differences 
between PE-only (55.6%) and FGR-only cases (53.8%), 
relative to controls (40%) (Table 4, Figure 1C).
Seropositivity for both CagA and VacA antibodies 
was associated with higher risk of  PE-FGR (OR 45.44; 
95% CI: 7.79-265.18). In fact, 87.5% of  PE-FGR preg-
nancies were CagA and VacA seropositive, compared 
to 22.4% in Ctrl group (Table 5, Figure 1D). Patients 
seropositive for VacA, but not for CagA, were nine 
controls (18.4%), one FGR (7.7%), and no PE women, 
while seropositivity for CagA only was a specific feature 
of  the PE-only group (Table 5). Seronegative women 
for both anti-CagA and VacA antibodies were only 9.4% 
in the PE-FGR group, while they were 59.2%, 35.3% 
and 53.8% in the Ctrl, PE-only and FGR-only groups, 
respectively (Table 5, Figure 1D). Importantly, CagA and 
VacA seronegativity was associated with a lower risk of  
developing pre-eclampsia complicated by fetal growth 
retardation (OR 0.04; 95% CI: 0.01-0.22).
UreC and UreE seropositivity was higher in PE-FGR 
pregnancies
We found significantly higher UreC and UreE seroposi-
tivity in PE-FGR patients (46.9%; P = 0.018 and 56.3%; 
P = 0.003, respectively) relative to controls (26.5% and 
24.5%, respectively) (Figure 2B and C), while there were 
no differences among groups for HspB, FlagA, UreA, 
and UreH (Table 4, Figure 2A and D-F). Odds ratios 
calculation showed higher risk of  developing PE-FGR in 
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Table 2  Clinical characteristics of study populations (categorical variables)  n  (%)
Variable Controls
(n  = 49)
PE-only
(n  = 17)
PE FGR
(n  = 32)
FGR-only
(n  = 13)
P  value5
Cesarean section delivery      15 (30.6)6,7,8  16 (94.1)6    29 (90.6)7        9 (69.2)8 6,7< 0.001; 80.022
Neonatal sex Male  19 (38.8)7  7 (41.2)    20 (62.5)7      6 (46.2) 70.043
Female 30 (61.2) 10 (58.8)  12 (37.5)      7 (53.8) NS
Nulliparae    31 (63.3)6,7  16 (94.1)6    27 (84.4)7    10 (76.9) 60.015; 70.047
Maternal risk factors 4 (8.2)   2 (11.8)1    8 (25.0)    1 (7.7) NS
Autoimmune diseases 1 (2.0)  2 (11.8)    4 (12.5) 0 (0) NS
Cardiovascular diseases 3 (6.1) 1 (5.9)    4 (12.5)    1 (7.7) NS
Family risk factors 202 (40.8)6    123 (70.6)6,10 134 (40.6)        2 (15.4)10 60.049; 100.004
Hypertension   9 (18.4)  8 (47.1)  10 (31.3)      2 (15.4) NS
Diabetes 10 (20.4)  3 (17.6)    5 (15.6) 0 (0) NS
Cardiovascular diseases   5 (10.2)  2 (11.8)  3 (9.4) 0 (0) NS
Other complications: FGR    0 (0.0)7,8     0 (0.0)9,10    32 (100)7,9       13 (100)8,10 7,8,9,10< 0.001
Early onset PE - 16 (94.1)  29 (90.6) - NS
Severe PE - 13 (76.5)  19 (59.4) - NS
HELLP syndrome -  3 (17.6)  2 (6.3) - NS
1One patient presented both maternal risk factors (autoimmune and cardiovascular diseases); 2Four patients presented two family risk factors (3 
hypertension and diabetes; 1 diabetes and cardiovascular disease); 3One patient presented two family risk factors (hypertension and diabetes); 4Five patients 
presented two family risk factors (4 hypertension and diabetes; 1 hypertension and cardiovascular disease). 5P values were calculated by chi-square test (χ 2).
6Comparison between controls and PE-only group; 7Comparison between controls and PE FGR group; 8Comparison between controls and FGR-only group; 
9Comparison between PE-only and PE FGR groups; 10Comparison between PE-only and FGR-only groups. NS: Non significant; PE: Pre-eclampsia; FGR: 
Fetal growth retardation; HELLP: Hemolysis-elevated liver enzymes-low platelets.
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Table 4  Seropositivity against Helicobacter pylori , cytotoxin-associated antigen A, vacuolating cytotoxin A, ureases A, C, E and H, 
heat shock protein B and flagellin A  n  (%)
Controls
(n  = 49)
All PE
(n  = 49)
PE-only
(n  = 17)
PE FGR
(n  = 32)
FGR-only
(n  = 13)
P  value1,2 Odds ratio1 (95% CI)
Helicobacter pylori     21 (42.9)3,5  42 (85.7)3 12 (70.6)   30 (93.8)5 6 (46.2) 3,5< 0.001   39.22 (2.83-30.04)
  535.56 (5.22-242.43)
CagA       11 (22.4)3,4,5  40 (81.6)3   11 (64.7)4   29 (90.6)5 5 (38.5) 3,5< 0.001 317.66 (5.25-59.49)
        40.038   45.20 (1.09-24.69)
  554.97 (9.24-326.88)
VacA     20 (40.8)3,5  37 (75.5)3   9 (52.9)  28 (87.5)5 6 (46.2)       30.005   34.89 (1.62-14.73)
5< 0.001   519.64 (3.75-102.98)
HspB 15 (30.6)  21 (42.9)   5 (29.4) 16 (50.0) 6 (46.2) NS
FlagA 13 (26.5)  22 (44.9)   6 (35.3) 16 (50.0) 5 (38.5) NS
UreA 10 (20.4)  13 (26.5)   4 (23.5)   9 (28.1) 3 (23.1) NS
UreC    13 (26.5)3,5  19 (38.8)3   4 (23.5)  15 (46.9)5 4 (30.8)       30.042 32.84 (1.04-7.75)
      50.018   54.02 (1.27-12.80)
UreE    12 (24.5)3,5  26 (53.1)3   8 (47.1)  18 (56.3)5 3 (23.1)      30.004   34.41 (1.59-12.26)
    50.003   56.29 (1.88-21.04)
UreH   8 (16.3) 13 (26.5)   5 (29.4)   8 (25.0) 4 (30.8) NS
1Adjusted for maternal age at delivery, pre-pregnancy body mass index, parity, and presence of maternal and family risk factors; 2P values were calculated 
by χ 2 test; 3Comparison between controls and all PE group; 4Comparison between controls and PE-only group; 5Comparison between controls and PE 
FGR group. CI: Confidence intervals; NS: Non significant; PE: Pre-eclampsia; FGR: Fetal growth retardation; CagA: Cytotoxin-associated antigen A; VacA: 
Vacuolating cytotoxin A; HspB: Heat shock protein B; FlagA: Flagellin A; Ure: Ureases. 
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Table 3  Leukocytes, platelets and liver enzymes in normal and pathological pregnancies
Variable Normal values 
in Italian female
population
range
Controls (n  = 49)
Median (25th-75th)
All PE (n  = 49)
Median (25th-75th)
PE-only (n  = 17)
Median (25th-75th)
PE FGR (n  = 32)
Median (25th-75th)
FGR-only (n  = 13)
Median (25th-75th)
P  value2
Total leukocyte count 
(1 × 103/μL)
  4.00-11.00 10.56 (9.21-11.65)3,7,5,6 12.03 (10.69-14.1)3 12.34 (10.71-13.83)5 11.83 (10.2-14.51)6 12.27 (11.21-13.47)7  30.004; 
70.045
 50.007; 
60.024
Neutrophils
(1 × 103/μL)
  8.27 (7.45-9.19) 10.09 (7.30-11.6) 10.15 (7.81-12.10)   9.92 (7.30-11.51)   9.34 (6.27-9.48) NS
(%) 45.0-73.0   75.8 (68.1-78.8)   76.7 (68.37-87.1)      80 (72.5-90.1)   72.1 (68.2-83.6)   64.4 (57.3-77.3) NS
Lymphocytes
(1 × 103/μL)
  2.02 (1.68-2.26)   2.08 (1.3-3.06)   1.86 (1.22-2.34)   2.08 (1.31-3.07)   3.15 (2.13-3.79) NS
(%) 19.0-47.0   18.7 (14-23.5)   17.4 (10.8-22.43) 14.55 (8.9-18.15)8   18.8 (11.1-23.2)   25.9 (17.4-34.3)8 80.047
Monocytes
(1 × 103/μL)
  0.54 (0.47-0.74)   0.59 (0.3-0.85)   0.61 (0.25-0.81)   0.58 (0.3-0.88)   0.89 (0.54-1.05) NS
(%) 3.0-9.0     5.4 (4.5-6)     5.3 (3-7.3)   4.15 (2.15-7.75)     5.4 (3.5-7.3)     6.1 (4.9-7.9) NS
Eosinophils
(1 × 103/μL)
  0.15 (0.09-0.19)3   0.05 (0.02-0.1)3   0.04 (0.02-0.11)   0.05 (0.03-0.1)   0.17 (0.03-0.33) 30.028
(%) 0.2-4.4     1.2 (0.9-1.8)3     0.5 (0.2-0.8)3   0.35 (0.1-0.8)     0.5 (0.2-0.8)     1.7 (0.2-2.4) 30.020
Basophils
(1 × 103/μL)
  0.02 (0.01-0.03)   0.02 (0.01-0.03)   0.03 (0.01-0.03)   0.02 (0.01-0.03)   0.01 (0-0.04) NS
(%) 0.1-1.3     0.2 (0.1-0.3)     0.2 (0.1-0.3)     0.2 (0.15-0.25)     0.2 (0.1-0.3)     0.1 (0-0.3) NS
Platelets
(1 × 103/μL)
150-400    219 (170-240)5    187 (126-228)    170 (111-214)5,8    191 (143-234)    235 (177-285)8  50.024; 
80.031
Platelets1
(1 × 103/μL)
150-400    219 (170-240)    191 (161-234) 180.5 (154-228)    191 (165-242)    235 (177-285) NS
ALT (U/L) < 34      15 (10-19)3,5      23 (14-46)3      26 (19-150)5,8   19.5 (13.5-35)      14 (10-21.5)8 30.006; 
50.002; 
80.026
ALT1 (U/L) < 34      15 (10-19)3      20 (14-31)3      25 (15-46)      18 (13-27)      14 (10-21.5) 30.023
AST (U/L) < 31   17.5 (14-19)3      21 (16-39)3,4      25 (16-123)8      20 (16-35.5)9      14 (12-18)4,8,9 30.029;  
40.018;   
80.031; 
90.026
AST1 (U/L) < 31   17.5 (14-19)      19 (15.5-33)      19 (15-39)   18.5 (16-32)      14 (12-18) NS
1Hemolysis-elevated liver enzymes-low platelets cases excluded; 2P values were calculated by non-parametric Kruskal-Wallis H test, with post-hoc analysis 
by Mann-Whitney U test. 3Comparison between controls and all PE group; 4Comparison between all PE and FGR-only groups; 5Comparison between 
controls and PE-only group; 6Comparison between controls and PE FGR group; 7Comparison between controls and FGR-only group; 8Comparison between 
PE-only and FGR-only groups; 9Comparison between PE-only and FGR-only groups. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NS: 
Non significant; PE: Pre-eclampsia; FGR: Fetal growth retardation. 
patients seropositive for UreC (OR 4.02, 95% CI: 1.27-12.8) 
and UreE (OR 6.29, 95% CI: 1.88-21.04) (Table 4).
Association among CagA/VacA seropositivity and 
leukocyte blood count, platelet count, and serum 
amino-transferases values
Considering seropositivities for CagA and/or VacA anti-
gens, we found that the total leukocyte count was signifi-
cantly decreased in VacA only seropositive patients rela-
tive to seronegative, CagA+/VacA- and CagA+/VacA+ 
patients (P = 0.003; P = 0.014 and P = 0.012, respectively, 
Table 6). Moreover, the basophiles percentage, but not 
total count, was significantly increased in CagA/VacA 
double seropositive compared to seronegative patients 
(P = 0.002, Table 6). No differences among groups were 
found for the other investigated parameters (Table 6). 
Analyzing amino-transferases levels after HELLP cases 
exclusion, ALT was significantly increased in CagA only 
seropositive patients relative to the other groups (P = 0.02; 
P = 0.025; P = 0.023, respectively, Table 6), while no dif-
ferences were found for AST levels (Table 6).
DISCUSSION
In the present study, we reported a direct association be-
tween H. pylori virulence and the onset of  pre-eclampsia 
complicated by FGR. Moreover, by investigating sero-
positivity for H. pylori virulence factors, we were able to 
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Figure 1  Percentage of Helicobacter pylori (A), CagA (B), VacA (C), and CagA/VacA (D) seropositive women in control, PE, PE FGR, and FGR groups. aP < 
0.05 between controls and PE-FGR; cP < 0.05 between controls and PE without FGR. �a���� ��toto�in-associated anti�en �; �ac��� �acuolatin� c�toto�in �; PE�� Pre-         
eclampsia; FGR�� Fetal �rowth retardation.
a
a
a,c
c
a
a
a
a
a
A B
C D
Cardaropoli S et al . Helicobacter pylori  virulence and pre-eclampsia
Table 5  Cytotoxin-associated antigen A/vacuolating cytotoxin A dual seropositivity  n  (%)
Controls
(n  = 49)
All PE
(n  = 49)
PE-only
(n  = 17)
PE FGR
(n  = 32)
FGR-only
(n  = 13)
P  value1,2 Odds ratio1 (95% CI)
CagA+VacA+     11 (22.4)3,4     37 (75.5)3      9 (52.9)     28 (87.5)4   5 (38.5) 3< 0.001 12.10 (3.76-38.91)
     40.001   45.44 (7.79-265.18)
CagA-VacA+   9 (18.4) 0 (0) 0 (0) 0 (0) 1 (7.7) NS
CagA+VacA- 0 (0.0)    3 (6.1)      2 (11.8)    1 (3.1) 0 (0.0) NS
CagA-VacA-    29 (59.2)3,4       9 (18.4)3      6 (35.3)     3 (9.4)4   7 (53.8)       30.001 0.13 (0.04-0.42)
4< 0.001 0.04 (0.01-0.22)
1Adjusted for maternal age at delivery, pre-pregnancy body mass index, parity, and presence of maternal and family risk factors; 2P values were calculated 
by chi-square test (χ 2); 3Comparison between controls and all PE group; 4Comparison between controls and PE FGR group. CI: Confidence intervals; NS: 
Non significant; CagA: Cytotoxin-associated antigen A; VacA: Vacuolating cytotoxin A; PE: Pre-eclampsia; FGR: Fetal growth retardation.
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distinguish pre-eclampsia and FGR without hypertension 
as different pathologies.
It is accepted that pre-eclamptic pregnancies, com-
plicated or not by FGR, are characterized by severe 
maternal inflammation[1]. Less is known about “pure” 
FGR pregnancies, probably because of  a biased classi-
fication system that considers FGR a secondary disease 
or a complication of  pre-eclampsia. We found elevated 
maternal leukocytes count, typical sign of  inflamma-
tion, in all pathological pregnancies relative to controls. 
However, while leukocytosis in PE patients, as previously 
reported[29,30], was mainly due to elevated neutrophils lev-
els, a typical marker of  bacterial infection[31], in FGR-only 
mothers, leukocytosis was due to increase in monocytes, 
eosinophils, and lymphocytes. Moreover, we found sig-
nificantly higher transaminases levels in the PE group, 
even after the exclusion of  HELLP cases, known to be 
characterized by elevated hepatic enzymes. The trigger 
of  this exacerbated inflammatory response still remains 
unknown.
Graham et al[21] previously demonstrated a direct as-
sociation between abnormal total leukocyte count and 
H. pylori-infection in patients with duodenal ulcer disease. 
They reported a significant fall in total white cell and neu-
trophils counts in patients successfully treated by H. pylori 
antibiotic therapy[21]. Moreover, they observed higher 
AST levels in CagA-positive patients, even after antibiotic 
treatment, thus assuming that AST levels are not directly 
associated with H. pylori infection[21]. Furthermore, we 
previously reported a correlation between H. pylori infec-
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Figure 2  Percentage of Ureases (A-D), HspB (E), and FlagA (F) seropositive women in control, PE, PE FGR, and FGR groups. aP < 0.05 vs controls. �sp��� 
�eat shock protein �; Fla���� Fla�ellin �; Ure�� Urease; PE�� Pre-eclampsia; FGR�� Fetal �rowth retardation.     
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tion and the onset of  pre-eclampsia during pregnancy, 
suggesting that this Gram-negative bacterium could cause 
or contribute to the etiopathogenesis of  pre-eclampsia[7], 
by inducing the pro-inflammatory state.
In the present study, we further investigated H. pylori 
and pre-eclampsia association by considering the main 
markers of  H. pylori virulence and infection persistence, 
which are useful for understanding the severity and char-
acteristics of  the infection.
H. pylori strains carrying the CagA antigen are known 
to be among the most virulent and are associated with 
increased inflammation[13]. VacA is a H. pylori toxin cru-
cial to promote and maintain bacterial colonization[14]. 
Importantly, combined seropositivity for both CagA and 
VacA directly correlates with elevated morbidity[32-34]. We 
previously reported a strong association between CagA 
positive H. pylori infection and the onset of  PE in Italian 
women[7]. In the present study, we also found that CagA/
VacA dual seropositivity is specifically associated with 
pre-eclampsia and, in particular, with PE complicated by 
FGR. In contrast, the absence of  both anti-CagA and 
anti-VacA antibodies is associated with a lower risk of  
PE. Interestingly, the association with CagA-/VacA+ was 
found only in controls and normotensive women with 
FGR pregnancies, while CagA+/VacA- patients belong to 
the PE groups. Our data suggest that the CagA antigen is 
associated with a more severe pattern, while VacA alone 
is not sufficient to cause the severe systemic inflammation 
typical of  PE. The highest leukocyte count and ALT level 
observed in CagA+/VacA- patients further corroborated 
this hypothesis, while subjects seropositive only for VacA 
were characterized by the lowest median leukocyte values 
(Table 6). CagA/VacA dual seropositivity was the most 
frequent condition in PE complicated by FGR patients 
(Table 5), and was associated with intermediate leukocyte 
and ALT values (Table 6). Therefore, we speculate that 
CagA, with or without VacA, may contribute to the onset 
of  pre-eclampsia, while VacA seropositivity could attenu-
ate CagA virulence. Our results indicate that severe (CagA 
positive) and persistent (VacA positive) maternal H. pylori 
infections are strongly associated to pre-eclampsia compli-
cated by feto-placental compromise, as indicated by FGR. 
Therefore, chronic and severe H. pylori infections could 
contribute not only to the exacerbated maternal inflam-
matory response leading to pre-eclampsia, but also to the 
abnormal placentation typical of  FGR.
Importantly, FGR without PE does not present sig-
nificant differences relative to physiological controls for 
either H. pylori (Table 3, Figure 1A) and CagA/VacA dual 
seropositivity (Figure 1D), suggesting that different etio-
pathogenetic mechanisms lead to “pure” FGR.
Another key H. pylori virulence factor is Urease, an 
enzyme that modifies environmental pH to allow H. 
pylori colonization[35]. Moreover, it helps to activate pro-
inflammatory cytokines production[15]. We determined se-
ropositivity for A, E and H urease subunits and for UreC 
in pre-eclamptic and/or FGR pregnant women relative 
to controls. In PE women relative to controls, we found 
significantly higher seropositivity only for the UreE 
subunit; the carrier of  nickel ions and pivotal for proper 
enzyme activity[36-38]. The rate of  seropositivity for UreC, 
the enzyme necessary for bacterial cell wall formation[39], 
was significantly higher in PE pregnancies complicated 
by FGR, as we previously showed for CagA/VacA dual-
seropositivity. These data suggest that UreE and UreC 
contribute to the onset of  both PE and PE-FGR.
Table 6  Hematological values and cytotoxin-associated antigen A/vacuolating cytotoxin A antigens
Variables Normal values 
in Italian female 
population range
CagA-VacA- (n  = 45)
Median (25th-75th)
CagA-VacA+ (n  =10)
Median (25th-75th)
CagA+VacA- (n  = 3)
Median (25th-75th)
CagA+VacA+ (n  = 53)
Median (25th-75th)
P  value2
Total leukocyte count 
(1 × 103/μL)
4.00-11.00        12.02 (10.6-13.13)3            8.95 (7.75-10.5)3,5,6         14.1 (12.4-16.34)5       11.27 (9.62-13.64)6 30.003; 
60.012; 
50.014
Neutrophils (1 × 103/μL)      10.02 (8.88-11.40)      7.45 (4.87-9.48)       12.75 (11.03-14.48)    8.43 (6.9-10.5) NS
(%) 45.0-73.0          78.8 (67.05-88.85)      71.9 (68.1-77.3)     83.4 (78.2-88.6) 72.05 (67.4-80) NS
Lymphocytes  (1 × 103/μL)      1.72 (1.11-2.85)      2.13 (1.68-2.13)     1.61 (0.93-2.28)      2.34 (1.63-3.07) NS
(%) 19.0-47.0    15.3 (8.9-23.2)      20.6 (17.4-23.5) 10.95 (5.7-16.2) 18.75 (14-23.3) NS
Monocytes (1 × 103/μL)      0.57 (0.26-0.89)    0.54 (0.43-0.6)     0.78 (0.68-0.88)        0.6 (0.44-0.84) NS
(%) 3.0-9.0      4.75 (2.15-6.85) 5.2 (4.9-6)   5.1 (4.8-5.4)  5.81 (4.3-7.4) NS
Eosinophils (1 × 103/μL)      0.05 (0.02-0.18)      0.09 (0.03-0.21)     0.06 (0.03-0.08)      0.06 (0.03-0.15) NS
(%) 0.2-4.4    0.55 (0.1-1.45) 1.2 (0.2-2)   0.4 (0.2-0.6)    0.58 (0.3-1.17) NS
Basophils (1 × 103/μL) 0.01 (0-0.02)      0.03 (0.01-0.03)     0.02 (0.02-0.03)      0.03 (0.01-0.04) NS
(%) 0.1-1.3 0.1 (0-0.2)    0.2 (0.2-0.3) 0.15 (0.1-0.2)     0.2 (0.2-0.3)  0.002
Platelets1 (1 × 103/μL) 150-400     222 (169-249)        175 (154-209.5)    214 (210-228)     191 (166-242) NS
ALT1 (U/L) < 34       16 (12.5-26)4   11 (9-12)5        32 (30-178)4,5,7        17 (11.5-24)7 40.020; 
50.025; 
70.023
AST1 (U/L) < 31         18 (15.5-23.5)   13 (12-19) 58 (15-143) 18 (14.5-26) NS
1Hemolysis-elevated liver enzymes-low platelets cases excluded; 2P values were calculated by non-parametric Kruskal-Wallis H test, with post-hoc analysis 
by Mann-Whitney U test; 3Comparison between CagA-VacA- and CagA-VacA+ groups; 4Comparison between CagA-VacA- and CagA+VacA- groups; 
5Comparison between CagA-VacA+ and CagA+VacA- groups; 6Comparison between CagA-VacA+ and CagA+VacA+ groups; 7Comparison between 
CagA+VacA- and CagA+VacA+ groups. CagA: Cytotoxin-associated antigen A; VacA: Vacuolating cytotoxin A; ALT: Alanine aminotransferase; AST: 
Aspartate aminotransferase; NS: Non significant.
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Even though pre-eclampsia has been extensively in-
vestigated, the only effective therapeutic option remains 
a timed, programmed delivery. Our data clearly demon-
strate a direct correlation between severe and persistent 
H. pylori infection and the onset of  PE complicated by 
FGR, opening up attractive perspectives for the design 
of  new preventive and therapeutic interventions for pre-
eclampsia.
Although specific combinations of  different anti-
biotics are effective in eradicating H. pylori, antibiotics-
resistant strains are already emerging, thus decreasing 
the efficacy of  existing therapies[40]. Pharmacogenomics-
based treatments seem to increase the cure rates and new 
therapeutic approaches targeting H. pylori virulence fac-
tors are required[40]. In the case of  pregnancy-related dis-
eases, it would be preferable to prevent the exacerbated 
inflammation typical of  PE, thus avoiding pharmacologic 
therapies during pregnancy. Recently, several clinical trials 
and animal studies have focused on generating H. pylori 
recombinant vaccines[41,42]. They demonstrated the pos-
sibility of  eliciting an immunological response against H. 
pylori in humans, and to eradicate and protect against the 
infection in mice[43]. Experimental H. pylori vaccines have 
been created using bacterial urease and designed as oral 
preparations.
In conclusion, our results define pre-eclampsia com-
plicated by FGR and “pure FGR” as different patholo-
gies. Moreover, we demonstrated a direct role for H. pylori 
CagA/VacA positive strains in the etiopathogenesis of  
PE-FGR. Our data further emphasize the importance 
of  an accurate classification of  the multifactorial and 
multiform pre-eclamptic disease. It is generally accepted 
that PE is a syndrome that includes several pathologies 
with different etiopathogenesis but with similar clinical 
manifestations. For this reason, PE is usually classified on 
the basis of  symptoms severity (moderate or severe) or 
of  symptoms onset (early- or late-onset PE). We strongly 
believe that, as demonstrated by the present study, pre-
eclampsia should also be classified as placental (with feto-
placental involvement) or maternal (without feto-placental 
compromise)[44], both of  which may have early or late 
onset. This classification will lead to a better management 
of  this devastating pregnancy-related disorder. Further 
studies are required to identify specific H. pylori-related 
therapeutic targets.
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